Treatment of a patient with genotype 7 hepatitis C virus infection with sofosbuvir and velpatasvir

Hepatology. 2016 Sep;64(3):983-5. doi: 10.1002/hep.28636. Epub 2016 Jun 14.

Abstract

During a phase 3 study evaluating the combination of sofosbuvir-velpatasvir for 12 weeks in patients with genotype 1, 2, 4, 5, and 6 hepatitis C virus (HCV) infection, we enrolled a patient who was subsequently found to be infected with genotype 7 HCV. This patient tolerated the study regimen well and achieved sustained virological response 12 weeks after treatment (SVR12). (Hepatology 2016;64:983-985).

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antiviral Agents / therapeutic use*
  • Carbamates / therapeutic use*
  • Drug Combinations
  • Genotype
  • Hepacivirus / genetics*
  • Hepatitis C / drug therapy*
  • Hepatitis C / virology
  • Heterocyclic Compounds, 4 or More Rings / therapeutic use*
  • Humans
  • Male
  • Sofosbuvir / therapeutic use*

Substances

  • Antiviral Agents
  • Carbamates
  • Drug Combinations
  • Heterocyclic Compounds, 4 or More Rings
  • sofosbuvir-velpatasvir drug combination
  • Sofosbuvir